KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Non Operating Income (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Non Operating Income for 11 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 9.49% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, down 27.19% year-over-year, with the annual reading at $4.7 million for FY2025, 27.19% down from the prior year.
  • Non Operating Income hit $1.5 million in Q4 2025 for Arbutus Biopharma, up from $917000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.8 million in Q2 2024 to a low of -$750000.0 in Q3 2021.
  • Historically, Non Operating Income has averaged $701550.0 across 5 years, with a median of $1.1 million in 2023.
  • Biggest five-year swings in Non Operating Income: soared 1655.42% in 2023 and later plummeted 46.78% in 2025.
  • Year by year, Non Operating Income stood at -$525000.0 in 2021, then skyrocketed by 220.0% to $630000.0 in 2022, then skyrocketed by 127.78% to $1.4 million in 2023, then decreased by 2.37% to $1.4 million in 2024, then increased by 9.49% to $1.5 million in 2025.
  • Business Quant data shows Non Operating Income for ABUS at $1.5 million in Q4 2025, $917000.0 in Q3 2025, and $1.0 million in Q2 2025.